0001209191-21-066852.txt : 20211124 0001209191-21-066852.hdr.sgml : 20211124 20211124183441 ACCESSION NUMBER: 0001209191-21-066852 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211117 FILED AS OF DATE: 20211124 DATE AS OF CHANGE: 20211124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: EVNIN LUKE CENTRAL INDEX KEY: 0001134657 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448497 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET, 54TH STREET CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Todd CENTRAL INDEX KEY: 0001473930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448496 MAIL ADDRESS: STREET 1: THE JOHN HANCOCK TOWER STREET 2: 200 CLARENDON STREET 54TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2014, L.P. CENTRAL INDEX KEY: 0001609492 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448498 BUSINESS ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 425-9200 MAIL ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2014 (B), L.P. CENTRAL INDEX KEY: 0001609493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448495 BUSINESS ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02124 BUSINESS PHONE: (617) 425-9200 MAIL ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM Asset Management Investors BV2014 LLC CENTRAL INDEX KEY: 0001609495 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448494 BUSINESS ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 425-9200 MAIL ADDRESS: STREET 1: C/O MPM ASSET MANAGEMENT LLC STREET 2: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BIOVENTURES 2018 (B), L.P. CENTRAL INDEX KEY: 0001729504 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448491 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER NAME: FORMER CONFORMED NAME: MPM BIOVENTURES 2018 (B) LP DATE OF NAME CHANGE: 20180126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM ASSET MANAGEMENT INVESTORS BV2018 LLC CENTRAL INDEX KEY: 0001734817 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448490 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2014 LLC CENTRAL INDEX KEY: 0001765021 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448493 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MPM BioVentures 2014 GP LLC CENTRAL INDEX KEY: 0001765091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39401 FILM NUMBER: 211448492 BUSINESS ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 450 KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: iTeos Therapeutics, Inc. CENTRAL INDEX KEY: 0001808865 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 857-204-4583 MAIL ADDRESS: STREET 1: 139 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-17 0 0001808865 iTeos Therapeutics, Inc. ITOS 0001609492 MPM BioVentures 2014, L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001134657 EVNIN LUKE C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001473930 Foley Todd C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001609493 MPM BioVentures 2014 (B), L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001609495 MPM Asset Management Investors BV2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001765021 MPM BioVentures 2014 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001765091 MPM BioVentures 2014 GP LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001729504 MPM BIOVENTURES 2018 (B), L.P. C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 0001734817 MPM ASSET MANAGEMENT INVESTORS BV2018 LLC C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142 0 0 1 0 Common Stock 2021-11-17 4 J 0 15671 0.00 D 3119320 I See Footnote Common Stock 2021-11-22 4 S 0 9307 37.16 D 3110013 I See Footnote Common Stock 2021-11-22 4 S 0 11807 37.81 D 3098206 I See Footnote Common Stock 2021-11-23 4 S 0 19645 36.21 D 3078561 I See Footnote Common Stock 2021-11-23 4 S 0 359 36.50 D 3078202 I See Footnote Common Stock 2021-11-24 4 S 0 4868 35.20 D 3073334 I See Footnote Common Stock 2021-11-24 4 S 0 18343 36.05 D 3054991 I See Footnote Common Stock 2021-11-24 4 S 0 13126 37.02 D 3041865 I See Footnote Represents a pro rata in-kind distribution from MPM BioVentures 2014(B), L.P. ("BV 2014(B)") and MPM BioVentures 2018(B), L.P. ("BV 2018(B)") to its respectve limited partners for no consideration. The shares were distributed as follows: 10,424 by BV 2014(B) and 5,247 by BV 2018(B). The shares are held as follows: 1,771,303 by MPM BioVentures 2014, L.P. ("BV 2014"), 97,289 by BV2014(B), 60,967 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 1,118,717 by MPM BioVentures 2018, L.P. ("BV 2018"), 48,966 by BV 2018(B) and 22,078 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. The shares were sold as follows: 5,545 by BV 2014, 191 by AM BV2014, 3,502 by BV 2018 and 69 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.58 to $37.555 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,765,758 by BV 2014, 97,289 by, 60,776 by AM BV2014, 1,115,215 by BV 2018, 48,966 by BV 2018(B) and 22,009 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 7,034 by BV 2014, 242 by AM BV2014, 4,443 by BV 2018 and 88 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.58 to $38.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,758,724 by BV 2014, 97,289 by BV 2014(B), 60,534 by AM BV2014, 1,110,772 by BV 2018, 48,966 by BV 2018(B) and 21,921 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 11,704 by BV 2014, 403 by AM BV2014, 7,392 by BV 2018 and 146 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $36.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,747,020 by BV 2014, 97,289 by BV 2014(B), 60,131 by AM BV2014, 1,103,380 by BV 2018, 48,966 by BV 2018(B) and 21,775 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 214 by BV 2014, 7 by AM BV2014, 135 by BV 2018 and 3 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.48 to $36.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,746,806 by BV 2014, 97,289 by BV 2014(B), 60,124 by AM BV2014, 1,103,245 by BV 2018, 48,966 by BV 2018(B) and 21,772 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 2,900 by BV 2014, 100 by AM BV2014, 1,832 by BV 2018 and 36 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.82 to $35.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,743,906 by BV 2014, 97,289 by BV 2014(B), 60,024 by AM BV2014, 1,101,413 by BV 2018, 48,966 by BV 2018(B) and 21,736 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 10,929 by BV 2014, 376 by AM BV2014, 6,902 by BV 2018 and 136 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.83 to $36.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,732,977 by BV 2014, 97,289 by BV 2014(B), 59,648 by AM BV2014, 1,094,511 by BV 2018, 48,966 by BV 2018(B) and 21,600 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. The shares were sold as follows: 7,820 by BV 2014, 269 by AM BV2014, 4,939 by BV 2018 and 98 by AM BV2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.85 to $37.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The shares are held as follows: 1,725,157 by BV 2014, 97,289 by BV 2014(B), 59,379 by AM BV2014, 1,089,572 by BV 2018, 48,966 by BV 2018(B) and 21,502 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing. /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014, L.P. 2021-11-24 /s/ Luke Evnin 2021-11-24 /s/ Todd Foley 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC, the general partner of MPM BioVentures 2014 (B), L.P. 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the manager of MPM Asset Management Investors BV2014 LLC 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2014 LLC, the managing member of MPM BioVentures 2014 GP LLC 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018 (B), L.P. 2021-11-24 /s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the manager of MPM Asset Management Investors BV2018 LLC 2021-11-24